Extreme obesity is not associated with worse outcomes after surgery for renal cell carcinoma (RCC), according to a study.
A team led by E. Jason Abel, MD, of the University of Wisconsin School of Medicine and Public Health in Madison, studied 843 patients who underwent surgery for RCC. Of these, 100 had a body mass index (BMI) of 40 kg/m2 or higher (extreme obesity) 743 patients had a lower BMI. Extreme obese was not associated with an increased likelihood of blood transfusion, longer hospital length of stay, or 30-day hospital readmission compared with the lower-BMI group, Dr. Abel’s group reported online ahead of print in BJU International. The groups showed no significant differences in major complications, 90-day mortality, and overall, cancer-specific, or recurrence-free survival.
The 5-year overall, cancer-specific, and recurrence-free survival rates for the extremely obese group were 70%, 87.9%, and 90.6%, respectively. The rates for the patients with a BMI less than 40 kg/m2 were 69%, 78.4%, and 84.1%, respectively. None of these between-group differences was statistically significantly.
“Extreme obesity is not associated with worse peri-operative or cancer outcomes after surgery for RCC,” the authors concluded. “Surgery should remain a standard treatment option in well selected morbidly obese patients.”